1. Home
  2. YQ vs MDXH Comparison

YQ vs MDXH Comparison

Compare YQ & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YQ

17 Education & Technology Group Inc.

HOLD

Current Price

$2.30

Market Cap

22.2M

Sector

Real Estate

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.72

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
YQ
MDXH
Founded
2012
2003
Country
China
Belgium
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
22.2M
21.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
YQ
MDXH
Price
$2.30
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
6.5K
15.5M
Earning Date
06-09-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.68
$0.40
52 Week High
$6.45
$5.33

Technical Indicators

Market Signals
Indicator
YQ
MDXH
Relative Strength Index (RSI) 59.25 64.73
Support Level $1.84 $0.68
Resistance Level $2.63 $2.23
Average True Range (ATR) 0.23 0.11
MACD 0.03 0.04
Stochastic Oscillator 81.11 43.29

Price Performance

Historical Comparison
YQ
MDXH

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: